Head-To-Head Analysis: Nexalin Technology (NASDAQ:NXL) and Diadexus (OTCMKTS:DDXS)

Nexalin Technology (NASDAQ:NXL) and Diadexus (OTCMKTS:DDXS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, analyst recommendations, earnings and risk.

Valuation and Earnings

This table compares Nexalin Technology and Diadexus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexalin Technology	$300,000.00	25.60	-$8.22 million	($0.47)	-0.74
Diadexus	N/A	N/A	N/A	N/A	N/A

Diadexus has lower revenue, but higher earnings than Nexalin Technology.

Profitability

This table compares Nexalin Technology and Diadexus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexalin Technology	-3,018.12%	-191.88%	-166.43%
Diadexus	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and target prices for Nexalin Technology and Diadexus, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexalin Technology	1	0	0	0	1.00
Diadexus	0	0	0	0	0.00

Given Diadexus’ higher possible upside, analysts clearly believe Diadexus is more favorable than Nexalin Technology.

Insider and Institutional Ownership

0.7% of Nexalin Technology shares are held by institutional investors. 16.9% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

About Diadexus

Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio intends to treat cardiovascular diseases. The company was founded on November 27, 1995 and is headquartered in South San Francisco, CA.